Corvista Health, Inc.
CorVista Health is dedicated to transforming cardiovascular care by developing innovative, non-invasive diagnostic solutions using machine learning and artificial intelligence. Their mission is to enable earlier detection, improve patient outcomes, and provide equitable access to high-quality cardiovascular diagnostics, especially in underserved and low-resource settings. They provide actionable cardiac diagnostics at the point of care, applying advanced machine learning for rapid and accurate diagnosis of cardiac disease, including coronary artery disease, pulmonary hypertension, and heart failure with preserved ejection fraction.
Industries
Nr. of Employees
small (1-50)
Corvista Health, Inc.
3 Bethesda Metro Center, Suite 700, Bethesda, MD 20814
Products
Non-invasive point-of-care cardiac diagnostic system
A point-of-care capture device combined with cloud-based analytics that collects non-invasive cardiac and hemodynamic signals, applies machine-learned algorithms, and delivers clinician-facing diagnostic reports for conditions including coronary artery disease and pulmonary hypertension; designed for single-visit, multi-condition assessment and internet-deployable operation.
Non-invasive point-of-care cardiac diagnostic system
A point-of-care capture device combined with cloud-based analytics that collects non-invasive cardiac and hemodynamic signals, applies machine-learned algorithms, and delivers clinician-facing diagnostic reports for conditions including coronary artery disease and pulmonary hypertension; designed for single-visit, multi-condition assessment and internet-deployable operation.
Services
Design and conduct of blinded, multi-site clinical validation studies for diagnostic algorithms including independent dataset validation and subgroup analyses to produce regulatory-grade evidence.
Remote and cloud-based development of supervised ML models, including feature engineering, iterative training, and performance testing on physiological signal datasets for multi-condition cardiac detection.
Support for forming strategic partnerships, memoranda of understanding, and joint evaluations to enable regional deployment, licensing, and distribution.
Design and conduct of blinded, multi-site clinical validation studies for diagnostic algorithms including independent dataset validation and subgroup analyses to produce regulatory-grade evidence.
Remote and cloud-based development of supervised ML models, including feature engineering, iterative training, and performance testing on physiological signal datasets for multi-condition cardiac detection.
Support for forming strategic partnerships, memoranda of understanding, and joint evaluations to enable regional deployment, licensing, and distribution.
Expertise Areas
- Point-of-care cardiovascular diagnostics
- Supervised machine learning model development and validation for clinical use
- Non-invasive hemodynamic assessment and cardiac parameter estimation
- Blinded multi-center clinical study design and execution
Key Technologies
- Supervised machine learning for diagnostic classification and regression
- Orthogonal voltage gradient (OVG) signal acquisition
- Photoplethysmography (PPG)
- Cloud-based signal processing and secure web portal delivery
News & Updates
CorVista announced a presentation of data validating its non-invasive algorithm for pulmonary hypertension detection, demonstrating high sensitivity and specificity.
The FDA cleared the CorVista System with Pulmonary Hypertension Add-On, enabling non-invasive detection of pulmonary hypertension.
Charles R. Bridges, M.D., Sc.D., was appointed as the new Chief Scientific Officer to lead clinical development.
CorVista's non-invasive system is designed to evaluate multiple cardiovascular conditions in a single visit.
Preliminary data shows the system's potential to detect elevated left ventricular end-diastolic pressure, aiding in early diagnosis of HFpEF.
CorVista announced a presentation of data validating its non-invasive algorithm for pulmonary hypertension detection, demonstrating high sensitivity and specificity.
The FDA cleared the CorVista System with Pulmonary Hypertension Add-On, enabling non-invasive detection of pulmonary hypertension.
Charles R. Bridges, M.D., Sc.D., was appointed as the new Chief Scientific Officer to lead clinical development.
CorVista's non-invasive system is designed to evaluate multiple cardiovascular conditions in a single visit.
Preliminary data shows the system's potential to detect elevated left ventricular end-diastolic pressure, aiding in early diagnosis of HFpEF.